Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily.
about
Guidelines for the treatment of childhood-onset Graves' disease in Japan, 2016Current and emerging treatment options for Graves' hyperthyroidism.The calcium-phosphate balance, modulation of thyroid autoimmune processes and other adverse effects connected with thyroid arterial embolizationEpidemiology, management and outcomes of Graves' disease-real life data.Free Thyroxine, Anti-Thyroid Stimulating Hormone Receptor Antibody Titers, and Absence of Goiter Were Associated with Responsiveness to Methimazole in Patients with New Onset Graves' Disease.Preventing postoperative hypocalcemia in patients with Graves disease: a prospective study.Methimazole associated neutropenia in a preterm neonate treated for hyperthyroidismUnusual Synchronous Methimazole-Induced Agranulocytosis and Severe Hepatotoxicity in Patient with Hyperthyroidism: A Case Report and Review of the Literature.Characteristics of Korean Patients with Antithyroid Drug-Induced Agranulocytosis: A Multicenter Study in KoreaAntithyroid drug induced a granulocytosis: what still we need to learn?Methimazole Induced Total Myeloid Aplasia with Delayed Recovery Despite Granulocyte Colony Stimulating Factor (G-CSF): Marrow Progenitor Recovery KineticsSepsis mimicking thyroid storm in a patient with methimazole-induced agranulocytosisCholestyramine Use for Rapid Reversion to Euthyroid States in Patients with Thyrotoxicosis.Successful Re-administration of Low-dose of Methimazole (MMI) in Graves' Disease Patients Who Experienced Allergic Cutaneous Reactions to MMI at Initial Treatment and Had Received Long-term Propylthiouracil (PTU).Periodic Granulocyte Count Measuring Is Useful for Detecting Asymptomatic Agranulocytosis in Antithyroid Drug-Treated Patients with Graves' DiseaseRelationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves' diseaseThe Brazilian consensus for the diagnosis and treatment of hyperthyroidism: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.Diagnosis and management of Graves disease: a global overview.Nonchemotherapy drug-induced neutropenia and agranulocytosis: could medications be the culprit?Thyroid disease in pregnancy: new insights in diagnosis and clinical management.Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if any).Emphasis on the early diagnosis of antithyroid drug-induced agranulocytosis: retrospective analysis over 16 years at one Chinese center.Delayed methimazole-induced agranulocytosis in a 6-year old patient with Graves' disease.A Report of Three Girls with Antithyroid Drug-Induced Agranulocytosis; Retrospective Analysis of 18 Cases Aged 15 Years or Younger Reported between 1995 and 2009.Association of HLA-B and HLA-DRB1 polymorphisms with antithyroid drug-induced agranulocytosis in a Han population from northern China.Clinical Trial of Four Weeks of Combination Therapy with Low-dose Methimazole and a Cholesterol Absorption Inhibitor as the Initial Treatment for Childhood-onset Graves' DiseaseLithium Carbonate in the Treatment of Graves' Disease with ATD-Induced Hepatic Injury or Leukopenia.Rare NOX3 Variants Confer Susceptibility to Agranulocytosis During Thyrostatic Treatment of Graves' Disease.
P2860
Q33594405-AFD55E6A-5974-42F8-8A0A-0F7651C93AE0Q33635029-1C58A3EE-141E-4EAB-95AC-4977B57F7C32Q33691920-66033393-6B96-4908-B4D5-16BD795E2C11Q33700874-0E754617-B223-4788-88D9-D5FBE49C098FQ33889900-9E831DFA-6F97-4E0F-8552-4C148FF4B878Q35054589-0D820FE8-E705-4524-A988-20CCC5D53838Q35164542-B3E5D796-3773-4DD6-A517-79E68CA53834Q35594705-028A849D-CDE5-4BAB-A675-48CCF8135BE3Q36489118-E8D64241-CDE3-4396-9B4B-84B9421DF5C0Q36869165-4FDEA0C8-EA6E-4C6D-96C0-216506829FAAQ37048443-D9358DC8-7FBF-4AC9-837C-FC3223040DE4Q37078129-F59BFFF3-9507-42C8-B979-2ADE507737D2Q37316052-BF53C9C9-8F5A-4368-BD4C-22504FC0C75EQ37521098-B47AF715-7EB6-483A-84D9-71DBFEF34D53Q37562888-142BDEBD-6B36-4AE8-A503-3C1F40B4D192Q37628656-71885899-B773-476C-A520-B7CE6489D9E2Q38107399-65F3B292-EFCE-4F60-A98B-C95ADF8826A8Q38152621-C605DE67-7A8C-4512-85D7-09B784D34E0DQ38240000-B2DE682F-AABE-4296-B733-0F1A43030746Q38641495-4FF5E7EE-EF1E-4FA5-9D20-D2441E891C71Q38869637-9DF56417-DCBD-4B6C-85B3-10536CF4592CQ38942929-3B09E684-BDEC-44BF-8AD1-4B9F8B15238BQ38949100-511AA599-3A84-49A7-9513-14569B76D0BBQ40329413-0AA89477-86FD-462A-BF95-06702795C8D3Q41696976-947DFAC4-D6BE-4321-A684-0A6DDFAE3827Q41954553-FA122B3F-63B9-4C14-9E95-1119CA492920Q43191847-A8CACCFD-6B97-4655-8FA8-1E90106D118DQ51012541-87F43E77-06A0-4EE5-9132-90486B3157B5
P2860
Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Methimazole-induced agranulocy ...... g daily than with 15 mg daily.
@en
Methimazole-induced agranulocy ...... g daily than with 15 mg daily.
@nl
type
label
Methimazole-induced agranulocy ...... g daily than with 15 mg daily.
@en
Methimazole-induced agranulocy ...... g daily than with 15 mg daily.
@nl
prefLabel
Methimazole-induced agranulocy ...... g daily than with 15 mg daily.
@en
Methimazole-induced agranulocy ...... g daily than with 15 mg daily.
@nl
P2093
P356
P1433
P1476
Methimazole-induced agranulocy ...... g daily than with 15 mg daily.
@en
P2093
Eijun Nishihara
Kazuna Takata
Mitsuru Ito
Nobuyuki Amino
Shuji Fukata
Sumihisa Kubota
Takumi Kudo
P304
P356
10.1089/THY.2008.0364
P577
2009-06-01T00:00:00Z